Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060504 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL19900778 | 0.81 | — | — | |
| SCHEMBL4121086 | 0.79 | CYP3A4 (0.37) | KDM4EKMT2ACYP1A2 | |
| SCHEMBL1515612 | 0.79 | — | — | |
| SCHEMBL18935464 | 0.78 | KDM4E (0.40) | KDM4EKMT2ADPP9DPP7DPP4 | |
| SCHEMBL18934853 | 0.78 | CYP1A2 (0.47) | KDM4EKMT2ADPP9DPP7DPP4 | |
| SCHEMBL4133242 | 0.77 | CYP3A4 (0.40) | KDM4EKMT2ACYP1A2 | |
| SCHEMBL21661391 | 0.76 | KDM4E (0.35) | KDM4EKMT2A | |
| SCHEMBL719286 | 0.76 | KDM4E (0.45) | KDM4EKMT2AKHKCYP1A2 | |
| Hydrochloric Acid SCHEMBL28097210 | 0.76 | CYP3A4 (0.39) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| WO-2017096045-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | KDM4E 3955/4885KMT2A 3584/4885DPP9 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.